natgillin/translations-raw huggingface dataset:
The cell of claims 1 or 17, wherein the domain or peptide or polypeptide capable of eliciting an immune response is selected from autoantigens, tumor antigens, virus antigens, parasite antigens, bacterial antigens and immunogenic fragments thereof. 
Stanica prema zahtjevu 1 ili 17, naznačena time što se domena ili peptid ili polipeptid sa sposobnošću izazivanja imunog odgovora, bira između autoantigena, tumorskih antigena, virusnih antigena, antigena parazita, bakterijskih antigena i njihovih imunogenih fragmenat
A process according to claim 1 wherein the equivalent ratio of 3-phenoxypropyl bromide to 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl ester is in the range of 1.0 to 3.0. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je odgovarajući omjer 3-fenoksipropil bromida do 2-hidroksi-2,2-ditien-2-iloctena kiselina 1-azabiciklo[2.2.2]okt-3(R)il estera u rasponu od 1.0 do 3.0.
In a yet further embodiment, the amine component of the amine salt of the compound of formula (II) is N(R40)3 where each R40 is independently C1-12 alkyl, or two R40 groups together with the nitrogen to which they are attached form a 4 to 6-membered heterocyclic ring and the remaining R40 group is C1-12 alkyl. In a further embodiment the amine component is selected from N(C1-6 alkyl)3, N-methyl morpholine or N-methyl piperidine. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time što aminska komponenta soli amina spoja s formulom (II) je N(R")s, gdje je svaki R" neovisno -H ili C,_,palkil, ili dvije R*" skupine zajedno s dušikom na koji su spojene tvore 4 do 6-člani heterociklički prsten i preostali R" je -H ili C,_,,alkil.
The method of claim 1 or 2, wherein the plurality of resource sets comprise a plurality of component carriers, the control channel search spaces being distributed over the component carriers, and wherein the secondary station (110) deduces from the mapping and presence of a control channel on a specific component carrier an indication of the resource set within which the allocated resource is located. 
Metoda iz patentnog zahtjeva 1 ili 2, gdje veliki broj skupova resursa sadrži veliki broj nositelja komponenti, prostore za pretragu kontrolnog kanala koji su distribuirani preko nositelja komponenti, i gdje sekundarna stanica (110) određuje iz mapiranja 1 prisustva kontrolnog kanala na specifičnom nositelju komponente indikaciju skupa resursa unutar kojeg je smješten alocirani resurs.
The antibody according to claim 1, wherein said antibody fragment is a Fab, Fab', F(ab')2, Fv or single chain Fv. 
Protutijelo u skladu s patentnim zahtjevom 1, pri čemu je navedeni dio protutijela Fab, Fab', F(ab')2, Fv ili jednolančani Fv.
a hollow voice prosthesis tubing fixedly attached on a first end of said elongated flexible body; and 
Sklop katetera (10) i govorne proteze, naznačen time što sadrži: izduženo savitljivo tijelo;
An in vitro method for producing an isolated IL-23p19 antibody according to any of claims 1-7 and 10-14, comprising providing a host cell or non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody. 
Postupak in vitro za proizvodnju izoliranog IL-23p19 antitijela prema bilo kojem od patentnih zahtjeva 1-7 1 10-14, naznačen time da osigurava stanicu domaćina ili neljudske transgene životinje ili transgene biljke ili biljne stanice pogodne za expresiju nadoknadive količine spomenutog antitijela.
the processing unit (11) of the first integrated circuit (10) is adapted to transfer the sensitive data from the first trust zone to the second trust zone for securely storing said data in the persistent memory area (21) of the second trust zone, 
- gdje je procesorska jedinica (11) u prvom integriranom krugu (10) prilagođena za prijenos osjetljivih podataka iz prvog područja povjerenja u drugo područje povjerenja radi sigurnog spremanja navedenih podataka u području trajne memorije (21) u drugom području povjerenja;
In accordance with one aspect of the present invention, an apparatus for preparing enzyme-immobilized beads includes: a) a first tank into which a mixed liquid containing an enzyme-containing material and an excipient is injected; b) a nozzle unit disposed at a lower end of the first tank, and comprising a nozzle which has an inner diameter of 0.1 mm to 1 mm and a cylindrical lower end and includes a liquid outlet cut perpendicularly to a vertical axis of the nozzle at the lower end thereof; and c) a second tank disposed below the nozzle unit and containing a calcium chloride solution. 
Uređaj za pripravu enzimski imobiliziranih zrna, naznačen time što sadrži: s a) prvi spremnik, u koji se ubrizgava miješana tekućina koja sadrži materijal koji sadrži enzim i pomoćnu tvar; b) mlazničnu jedinicu, koja se nalazi na donjem kraju prvog spremnika i sastoji se od mlaznice, gdje mlaznica ima unutarnji promjer od 0,1 mm do 1 mm i valjkasti donji kraj i uključuje izlaz tekućine odsječen okomito u odnosu na okomitu os mlaznice na njezinom donjem kraju; i c) drugi spremnik, koji se nalazi ispod mlaznične jedinice i sadrži otopinu kalcijevog klorida, gdje navedeni drugi spremnik sadrži napravu za ubrizgavanje zraka u otopinu kalcijevog klorida.
After wash of the column with PBS the captured material was eluted with 2-5 column bed volumes of 20 mM Na-phosphate buffer pH 8.4 containing 35% propylene glycol (PG). 
Nakon ispiranja kolone sa BS-om uhvaćeni je materijal eluiran sa 2-5 volumena korita kolone 20 u Na-fosfatnog pufera pH 8.4 koji je sadržavao 35%-tni propilen glikol (PG).
reacting the product of step (g) with 
(h) reakciji produkta iz koraka (g) s
A process according to claim 2, wherein for prevention of clogging of calcium sulphate precipitation, the chelating agent comprises ethylene diamine tetra acetic acid (EDTA). 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da za sprečavanje začepljenja taloženjem kalcijevim sulfatom, kelacijsko sredstvo sadržava etilen diamin tetra-octenu kiselinu (EDTA).
In some embodiments, the further nucleotide region comprises a biocleavable nucleotide region, such as a phosphate nucleotide sequence (a second region, region B), which may covalently link region A to a non-nucleotide moiety, such as a conjugate group, (a third region, or region C). 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da treća regija obuhvaća ne-nukleotidnu aktivnu tvar poput skupine konjugata kao što je sterol, primjerice kolesterol, ili ugljikohidrat poput klastera GalNac/GalNac.
The tablet as claimed in claim 9, wherein said tablet does not crack under room temperature conditions within 24 hours of being released from a tablet press. 
Tableta kao što je zahtijevano u patentnom zahtjevu 9, pri čemu navedena tableta ne puca pod uvjetima sobne temperature unutar 24 sata od kako je oslobođena iz preše za tablete.
ring A is an optionally substituted aryl or an optionally substituted heteroaryl; ring B is an optionally substituted aryl or an optionally substituted heteroaryl; 
prsten A je izborno supstituirani aril ili izborno supstituirani heteroaril; prsten B je izborno supstituirani aril ili izborno supstituirani heteroaril;
The invention also provides a process for the preparation of compounds of formula (I), in free or salt form, which comprises the steps of: 
Izum također predviđa postupak za pripravu spojeva formule (1) u slobodnom obliku ili u obliku soli, koji uključuje stupnjeve: (i)
wherein the agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or an insulin analogue; 
(a) sredstvo za liječenje dijabetesa je metformin, sulfonilurea, glinid, DPP-IV-inhibitor, glitazon, inzulin ili analog inzulina;
Homogenize membranes briefly until in suspension using a POLYTRON PT3100 (probe PT-DA 3007/2 at setting of 7000 rpm). 
* - Homogeniziraj membrane kratko do suspenzije uporabom POLYTRON PT 3100 (proba PT-DA 3007/2 namještanjem 7000 okr./min).
A composition according to any one of claims 1 to 4 or a compound according to any one of claims 5 to 9 for use in the prophylaxis or treatment of a disease state or condition which is selected from a carcinoma of the bladder, breast, colon, kidney, epidermal, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, endometrium, thyroid, prostate, or skin, a hematopoietic tumour of lymphoid lineage, a hematopoietic tumour of myeloid lineage, thyroid follicular cancer, a tumour of mesenchymal origin, a tumour of the central or peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoctanthoma, thyroid follicular cancer, or Kaposi's sarcoma; breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer and non-small cell lung carcinomas. 
Pripravak prema bilo kojem od zahtjeva 1 do 4 ili spoj prema bilo kojem od zahtjeva 5 do 9, za primjenu u profilaksi ili liječenju nekog bolesnog stanja ili bolesti iz skupine u koju spadaju karcinom mokraćnog mjehura, dojke, debelog crijeva, bubrega, epidermalni karcinom, karcinom jetre, pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, grlića maternice, sluznice maternice, štitnjače, prostate ili kože, hematopoetski tumor limfoidnog podrijetla, hematopoetski tumor mijeloidnog podrijetla, folikularni karcinom štitnjače, tumor mezenhimalnog podrijetla, tumor središnjeg ili perifernog živčanog sustava, melanom, seminom, teratokarcinom, osteosarkom, kseroderma pigmentosum, keratoktantom, folikularni karcinom štitnjače ili Kaposijev sarkom, karcinom dojke, karconom jajnika, karcinom debelog crijeva, karcinom jednjaka, karcinom skvamoznih stanica 1 nesitnostanični karcinomi pluća,
The antitumor agent or the combined product according to claim 12, wherein the antitumor agent having TS inhibitory action is a 5-FU antitumor agent or a pemetrexed sodium hydrate. 
Antitumorsko sredstvo ili kombinirani proizvod prema zahtjevu 11, naznačen/o time, da se kod antitumorskog sredstva koje ima inhibitorsko djelovanje na TS, radi o 5-FU-antitumorskom sredstvu ili pemetreksiranom natrijevom hidratu.
Nitrogen gas was bubbled through the solution for 1 minute and tetrakis(triphenylphosphine)palladium (9.24 mg, 0.008 mmol) was added. 
Plinoviti dušik propuhuje sc kroz otopinu 1 minutu, te se doda tetrakis(trifenilfosfin)paladij (9,24 mg, 0,008 mmol).
The compound for use according to claim 1, characterized in that the pain is a nociceptive pain, an inflammatory pain, a neuropathic pain, an idiopathic pain or a psychogenic pain, preferably an inflammatory pain or neuropathic pain. 
Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time da bol jest nociceptivna bol, upalna bol, neuropatska bol, idiopatska bol ili psihogena bol, preferirano upalna bol ili neuropatska bol.
A compound according to any one of claims 1 to 12 for use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of dehydroorotate dehydrogenase and wherein the pathological condition or disease is preferably selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis. 
Spoj sukladno bilo kojem od zahtjeva 1 do 12 za primjenu u liječenju patološkog stanja ili bolesti koji su skloni amelioraciji putem inhibicije dihidroorotat dehidrogenaze, naznačen time da patološko stanje ili bolest u najvećem broju slučajeva obuhvaća reumatoidni artritis, ankilozantni spondilitis, multiplu sklerozu, Wegenerovu granulomatozu, sistemski lupus eritematosus, psorijazu i sarkoidozu.
ring B is a 5-membered nitrogen-containing non-aromatic heterocycle optionally substituted by 1 to 3 substituents selected from 
prsten B je 5-člani ne-aromatski heterocikl koji sadrži dušik i opcijski je supstituiran s 1 do 3 supstituenta odabrana od sljedećih:
A conjugate according to any of claims 3 to 7 for use in the prevention and/or treatment of cancer. A composition comprising, together or separately: a polypeptide of SEQ ID NO: 1, a functionally equivalent variant thereof or a conjugate according to any of claims 3 to 7 and 
Polipeptid, ili njegova funkcionalno ekvivalentna varijanta, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je funkcionalno ekvivalentna varijanta polipeptid dobiven insercijom ili adicijom jedne aminokiseline u odnosu na polipeptid sa SEQ ID NO: 1.
a step of producing the compound of the formula (8) from the compound of the formula (9-S): (in the formula, Ts represents p-toluenesulfonyl, Et represents ethyl, and R1 represents a linear or branched C1-6 alkyl). 
[image] (u formuli Ts predstavlja p-toluensulfonil, Et predstavlja etil, a R1 predstavlja nerazgranati ili razgranati C1-6alkil).
The ST1 P01/r-hIL-18BP final titre was calculated by averaging the 10 individual titres obtained in each experiment. 
Titar (U/ml)- Recipročno razrjeđenju kod 50% odgovora x za pred-razrjeđenje Konačan titar STIP01/r-hIL-18BP bio je izračunat iz prosjeka 10 pojedinačnih titara iz svakog eksperimenta.
The composition of matter according to claim 8 or 9, wherein the amount of the protein according to SEQ ID No: 2 exceeds that of the protein according to SEQ ID No: 3. 
Pripravak tvari u skladu s patentnim zahtjevom 8 ili 9, naznačen time što je količina proteina u skladu sa SEQ ID No: 2 veća od one proteina u skladu sa SEQ ID No: 3.
metazachlor and quinmerac including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
B) metazaklor i kvinmerak uključujući njihove odgovarajuće izomere, kao i njihove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom.
In other embodiments, the present invention provides methods for reducing or preventing norleucine misincorporation in a protein or polypeptide expressed by a microorganism, the method comprising expressing the protein or polypeptide in the microorganism, wherein the microorganism is a microorganism de-repressed for methionine production. 
Postupak prema patentnom zahtjevu 1, naznačen time, da se eksprimiranje proteina ili polipeptida u mikroorganizmu provodi u odsutnosti metionina egzogeno dodanog u medij za uzgoj ili bez prihranjivanja metioninom.
A pharmaceutical composition according to claim 6 or 7 for use in treating, preventing, or reducing a disease in human selected from the group consisting of melanoma, glioma, glioblastomas, leukemia, and carcinornas of lung, breast, colon, kidney, liver, gastrointestinal tract, pancreas, prostate, head, and neck. 
Farmaceutsi pripravak prema patentnom zahtejvu 6 ili 7 za uporabu u liječenju, prevenciji, ili smanjenju bolesti kod ljudi odabranu iz skupine koja se sastoji od melanoma, glioma, glioblastoma, leukemije, 1 karcinoma pluća, dojke, debelog crijeva, bubrega, jetre, gastrointestinalnog sustava, gušterače, prostate, glave i vrata.
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation with a composition comprising 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju, koji sadrži formulaciju matrice s produljenim otpuštanjem, gdje formulacija matrice s produljenim otpuštanjem sadrži sastav koji sadrži:
The main body (7) of the inhaler (1) is oriented so that the strap underlies the base of the main body (7). 
Glavno tijelo (7) inhalatora (1) orijentirano je tako da vrpca prolazi ispod osnovice glavnog tijela (7).
The liquefied gas treatment system according to claim 3, wherein the sub LNG supply line (L24) includes a gas-liquid separator (46) configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (1.24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
wherein X2 is —O— or —S—, n3 is an integer from 1 to 6 and R2 is as defined above; wherein: is an integer from 0 to 10; 
Re -(CH-CH-ArrCH,-CH i gdje X, jest ili -S-, n' je cijeli broj od 1 do 6, a R? je kao što je gore definiran, h)
The process of claim 9, wherein the light stream after draining is pressed to produce a pressed light stream and a released stream comprising water and additional water soluble species derived from the non-ligno-cellulosic water soluble compounds. 
Proces iz bilo kojeg od patentnih zahtjeva 7 do 13, gdje je lagani tok nakon dreniranja pritisnut da se proizvede stisnuti lagani tok 1 oslobođeni tok koji sadrži vodu i dodatne u vodi topljive vrste dobivene iz ne-ligno-celuloznih u vodi topljivih spojeva.
In a preferred manner it is provided, that the abrasive body is formed from a plurality of layers and has a substrate layer. 
Alat za brušenje (1) sukladno zahtjevu 1, naznačen time što je abrazivno tijelo (6) načinjeno od više slojeva i ima sloj supstrata (7).
• GSM/GPRS communication means and corresponding antenna 
* > sredstvo za GSM/GPRS komunikaciju i odgovarajuću antenu
Said shoe 200 comprises a breathable and waterproof sole 211, which is substantially similar to those described earlier, and an assembly 212, which is associated with said sole in an upward region and is constituted by an external breathable upper 213, an internal lining 214 and, between them, a breathable and waterproof membrane 215, which is made for example of a material such as Gore-Tex® or the like. 
Navedena cipela 200 obuhvaća prozračni i vodootporni potplat 211, koji je u znatnoj mjeri nalik prethodno opisanim utjelovljenjima, 1 sklop 212, koji je povezan s navedenim potplatom u njegovom gornjem dijelu, a čine ga vanjsko prozračno gornjište 213, unutarnja podstava 214 1, između njih, prozračna 1 vodootporna membrana 215, koja je izrađena na primjer od Gore-Texa * ili sličnog materijala.
proteinase K as a stock solution, 
(ili) proteinazu K, u matičnoj otopini,
A method for the synthesis of Y,δ-dihydroxyisoleucine 1, or of a synthon for compound 1, comprising the step of methylating compound 3 or 3* with methyl iodide in the presence of lithium bis(trimethylsilyl)amide (LHMDS). 
Postupak sinteze Y,δ-dihidroksiizoleucina 1, ili sintona spoja 1, naznačen time, da obuhvaća korak metilacije spoja 3 ili 3* s metil jodidom u prisutnosti litij bis(trimetilsilil)amida (LHMDS). [image]
A therapeutic substance combination product containing at least one connexin-blocking agent and an acetylcholinesterase inhibitor (AChEI), for simultaneous, separate or sequential use for treating a patient suffering from a cognitive disorder, wherein said acetylcholinesterase inhibitor is: 
Terapijski kombinacijski produkt tvari koji sadrži najmanje jedno sredstvo koje blokira koneksin i inhibitor acetilkolinesteraze (AChEI), kao kombinacijske produkte za simultanu, odvojenu ili sekvencijalnu upotrebu, za liječenje kognitivnih poremećaja, pri čemu rečeni inhibitor acetilkolinesteraze (AChEl) jest donepezil ili njegova farmaceutska sol.
The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl or pyridyl; and R1 is C1-C6alkyl. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je X imidazolil, pirazolil, izotiazolil, tiazolil, izoksazolil, oksazolil ili piridil; i R1 je C1-C6alkil.
The method of claim 1, wherein, when the one available intra prediction mode is a DC mode, the two additional intra prediction modes include a planar mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja DC način, dva dodatna unutarokovirna načina predviđanja uključuje planarni 1 vertikalni način.
The pharmaceutical composition of any of claims 1 to 6, which is selected from the compounds of formula (Ia): Wherein: 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, koja je odabrana od spoja sa formulom (Ia):
a light chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 21 and a heavy chain variable domain having a sequence with at least 90% identity to SEO ID NO: 55; 
varijabilne domene lakog lanca koja ima slijed s najmanje 90% podudaranja sa SEQ ID NO: 21 i varijabilne domene teškog lanca koja ima slijed s najmanje 90% podudaranja sa SEQ ID NO: 55;
the first portion and second portion are arranged so that the first portion is substantially invisible below the predetermined temperature, but becomes visible when the predetermined temperature is reached or exceeded. 
(c) navedeni prvi dio (12') i drugi dio (12") su raspoređeni tako, da je navedeni prvi dio (12) uglavnom nevidljiv ispod spomenute predodređene temperature, ali postaje vidljiv kada se spomenuta predodređena temperatura dosegne ili premaši; naznačen time, da
Glatiramer acetate for use according to claim 1 or a medicament comprising glatiramer acetate for use according to claim 2, wherein the frequency and severity of an immediate post injection reaction or an injection site reaction is reduced relative to the daily subcutaneous administration of 20mg glatiramer acetate. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema patentnom zahtjevu 1, naznačen time, da smanjuje atrofiju mozga. Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
An aqueous pharmaceutical suspension, having a pH about 4.25 to about 9.43 adjusted by a buffer system, comprising, by weight/volume (g/100 mL), about 0.03% to about 4.80% of fexofenadine zwitterionic dihydrate Form I of formula (I) having a particle size of less than about 280 µm for at least about 90% of the fexofenadine zwitterionic dihydrate Form I; about 0.01% to about 020% of a wetting agent; 
PATENTNI ZAHTJEVI L ll. Vodena farmaceutska suspenzija, naznačena time što ima pH od otprilike 4,25 do otprilike 9,43 a podešen je puferskim sustavom, koja sadrži, težinski/volumno (g/100 ml), otprilike 0,03 % do otprilike 4,80 % dvojnoionskog dihidratnog Oblika I feksofenadina formule (1), veličine čestica manje od otprilike 280 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina;
In addition, compounds of the formula I exhibit improved physico-chemical characteristics compared with those of the prior art. 
Dodatno, spojevi formule I pokazuju poboljšana fizikalno-kemijska svojstva u usporedbi s onima u stanju tehnike.
providing a native Neisseria meningitidis serogroup A polysaccharide; 
(a) osiguravanje nativnog polisaharida iz bakterije Neisseria meningitidis seroskupina A;
In some embodiments, the condition associated with coronary arterial bypass graft surgery is selected from the group consisting of: bleeding; thrombotic vascular events such as thrombosis, restenosis; vein graft failure; artery graft failure; atherosclerosis, angina pectoris; myocardial ischemia; acute coronary syndrome myocardial infarction; heart failure; arrhythmia; hypertension; transient ischemic attack; cerebral function impairment; thromboembolic stroke; cerebral ischemia; cerebral infarction; thrombophlebitis; deep vein thrombosis; and, peripheral vascular disease. 
Spoj za uporabu prema zahtjevu 11 gdje se to stanje izabire iz grupe koja obuhvaća: krvarenje; trombotske vaskularne događaje kao što je tromboza, restenoza; zatajenje venskog presatka; zatajenje arterijskog presatka; aterosklerozu, anginu pektoris; ishemiju miokarda; akutni koronarni sindrom; infarkt miokarda; zatajenje srca; aritmiju; hipertenziju; prolazni ishemijski napad; poremećaj moždane funkcije; tromboembolijski moždani udar; cerebralnu ishemiju; cerebralni infarkt; tromboflebitis; duboku vensku trombozu; i perifernu vaskularnu bolest.
Antisense compositions and methods of making and using same 
ANTISENS KOMPOZICIJE I POSTUPCI ZA PRIPREMU I UPORABU ISTIH